Morphosys And Novartis Sign Delisting Agreement
June 20 (Reuters) -MORPHOSYS AG MORG.DE:
MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS
MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 2024, AND MAY 30, 2024, RESPECTIVELY
MORPHOSYS AG - NOVARTIS WILL OFFER MORPHOSYS SHAREHOLDERS EUR 68.00 PER SHARE IN CASH, CORRESPONDING TO ITS PRECEDING TAKEOVER OFFER
MORPHOSYS AG - DELISTING OFFER DOCUMENT IS EXPECTED TO BE PUBLISHED BY NOVARTIS IN EARLY JULY 2024
MORPHOSYS AG - BOTH DELISTING FROM FRANKFURT STOCK EXCHANGE AND DELISTING FROM NASDAQ ARE EXPECTED TO TAKE PLACE IN Q3 OF 2024
MORPHOSYS AG - DELISTING OFFER DOCUMENT IS EXPECTED TO BE PUBLISHED BY NOVARTIS IN EARLY JULY 2024 AFTER GERMAN FEDERAL FINANCIAL SUPERVISORY AUTHORITY ("BAFIN") HAS APPROVED ITS PUBLICATION
Source text for Eikon: ID:nEQ9wGspya
Further company coverage: MORG.DE
(Gdansk Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
